‘Huge deal’ therapy cuts migraine attacks

Image copyright Getty Pictures

A brand new approach to preventing migraines can cut the amount and severity of attacks, 2 clinical trials show.

About 50% of people on a single study halved the number of migraines that they had each month, which researchers at King’s College Hospital called a “huge deal”.

The therapy is the first specifically designed for avoiding migraine and uses antibodies to change the activity of chemicals in the mind.

Further studies will need to assess the long-term effects.

  • One in 7 people around the world live with the regular discomfort of migraine
  • Migraine is up to 3 times more common in women than guys
  • The Migraine Trust estimates you can find more than 190, 000 migraine episodes every day in the UK
  • People with head aches for fewer than 15 days per month have episodic migraine
  • If it is upon more than 15 days it is categorised as chronic migraine

Research has proven a chemical in the brain — calcitonin gene-related peptide or CGRP – is involved in both discomfort and sensitivity to sound and gentle in migraine.

Four drug companies are racing to build up antibodies that neutralise CGRP. A few work by sticking to CGRP, while some block the part of a brain cellular with which it interacts.

Clinical trials on 2 of the antibodies have now been released in the New England Journal associated with Medicine.

A single antibody, erenumab made by Novartis, was trialled on 955 individuals with episodic migraine.

At the start of the trial the particular patients had migraines on an typical of eight days a month.

The study found fifty percent of those given the antibody shots halved their number of migraine times per month. About 27% did possess a similar effect without treatment, which demonstrates the natural ebb and flow of the illness.

Another antibody, fremanezumab made by Teva pharmaceutical drugs, was trialled on 1, 140 patients with chronic migraine.

About 41% associated with patients halved their number of headache days compared with 18% without treatment.

Prof Peter Goadsby, who led the particular erenumab trials at the NIHR analysis centre at King’s, told the particular BBC: “It’s a huge deal since it offers an advance in understanding the problem and a designer migraine treatment.

“It reduces the particular frequency and severity of head aches.

“These patients may have parts of their life back and culture will have these people back functioning. inch

He mentioned other data, not published within the latest studies, suggested a 5th of patients had no migraine headaches at all after treatment.

Better option?

The antibodies are not the only precautionary drugs for migraine. Others consist of former epilepsy and heart disease supplements as well as botox.

But Simon Evans, the chief professional of Migraine Action, said individuals drugs came with a lot of side-effects plus did not work for everyone.

“Some doctors give sufferers a choice of being angry or fat-and-dosey and the drug they give them depends upon their answer, ” he mentioned.

The hope can be discovering CGRP and precisely concentrating on it with antibodies should result in fewer side-effects. Both studies state long-term safety data still needs to be researched.

The problem along with antibodies is they tend to be more costly to make than other therapies.

Prof Goadsby thinks individuals who get no benefit from current treatments or cannot cope with the particular side-effects are those most likely to advantage.

Dr Andy Dowson, who runs headache solutions in Kent and London, mentioned: “I am really enthusiastic we now have something new that’s coming, but we have to know cost, who will respond and much more detail as we go down the line.

“Chronic migraine is in the very best seven conditions for lifetime impairment and yet nothing much is done about this, maybe this is going to help all of us to make some progress. ”

Follow James on Twitter .

Related Subjects